The enrollment of around one-hundred-and-twenty patients into its investigation study into the treatment of acne scarring has been completed by acne research company Isolagen.
Focussing on moderate to sever acne scars, the acne treatments are underway and being administered at 7 different clinical US sites.
Isolagen CEO, Declan Daly, explains Isolagen have committed resources in order to advance this acne program and seeking additional funding.
“Concerning Isolagen’s pivotal clinical program on wrinkle correction, we expect to review the 6 month efficacy data on the Phase 3 study before 1st September this year.”
For more information of Isolagen, visit their website.